Sartorius Stedim stock confirms 2026 guidance before the Xetra open
Published on 10/22/2026 at 08:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance remains confirmed
- Sartorius Stedim reported EUR 2,289 million in sales revenue for the first nine months of 2026 on October 22, 2026.
- The company scheduled a conference call on its nine-month results for October 22, 2026, at 1:00 p.m. CEST.
- Sartorius Stedim stock trades pre-market at EUR 216.60 at 8:38 a.m. CEST at Lang & Schwarz on October 22, 2026.
On October 22, 2026, Sartorius Stedim Biotech reported first-nine-month sales revenue of EUR 2,289 million and confirmed its 2026 guidance in an EQS release. At 8:38 a.m. CEST, Sartorius Stedim stock was at EUR 216.60 in pre-market trading at Lang & Schwarz on October 22, 2026.
Nine-month results and guidance
Underlying EBITDA reached EUR 716 million, with a margin of 31.3 percent, while net profit was EUR 277 million. Management continued to expect constant-currency sales growth of around 6 to 10 percent and an underlying EBITDA margin slightly above 31 percent for 2026. The company also said the capital-expenditure-to-sales ratio is now expected to be around 13 percent. The figures and guidance were included in the company release.
Ahead of the Xetra open
The Lang & Schwarz pre-market indication was EUR 216.60 at 8:38 a.m. CEST on October 22, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Sartorius Stedim stock.
The group and today’s agenda
Sartorius Stedim Biotech supplies technologies and services that help biopharmaceutical companies develop and manufacture medicines. The company scheduled a conference call on its nine-month results for October 22, 2026, at 1:00 p.m. CEST. Market context: Market report CAC 40.
